<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02454231</url>
  </required_header>
  <id_info>
    <org_study_id>UFlorence</org_study_id>
    <nct_id>NCT02454231</nct_id>
  </id_info>
  <brief_title>Monocentric Trial: Stem Cell Emergency Life Threatening Limbs Arteriopathy (SCELTA)</brief_title>
  <acronym>SCELTA</acronym>
  <official_title>Monocentric Randomized Study for the Therapy of Critic Limb Ischemia With Bone Marrow- or Peripheral Blood-derived Stem Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florence</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tuscany Region</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florence</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators designed a randomized clinical trial (stem cell emergency life threatening
      arteriopathy or SCELTA) to compare the therapeutic efficacy of the auto-transplant of
      enriched circulating EPCs (ECEPCs) with auto-transplant of BM-MNCs. ECEPCs, obtained by
      immunoselection of CD14+ and CD34+ cells, or BM-MNCs, were injected intramuscularly in the
      affected limb of patients with critical limb ischemia (CLI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Peripheral arterial disease comprises a clinical spectrum that extends from no symptoms to
      presentation with critical limb ischemia (CLI), which is a very invalidating condition
      characterized by rest pain, march inability, trophic lesions and unavoidable progression to
      major amputations, which are burdened by a high mortality in the first year. The
      pathophysiology of CLI often associates with a defect in the development of collateral
      vessels and angiogenesis, a process which refers to the formation of new blood vessels into
      tissue, due to circulating endothelial progenitor cells (EPCs) and vascular progenitor cells.
      In the last few years, significant improvement of this condition has been reported following
      bone marrow (BM) autotransplant or autotransplant of peripheral EPCs mobilized from BM
      through the injection of granulocyte-colony stimulatory factor (G-CSF). In a previous study,
      the investigators found that individually variable proportions of circulating CD14+ cells
      expressed low levels of CD34 (CD14+CD34low) and revealed the functional phenotype of EPCs.
      The investigators therefore designed a monocentric randomized clinical trial to compare the
      therapeutic efficacy of BM autotransplant with the autotransplant of a population of
      circulating CD34+ and CD14+CD34low enriched by a closed sterile immunomagnetic system
      (enriched circulating EPCs or ECEPCs), without a previous EPC mobilization from BM.

      Patients will be evaluated for clinical parameters and ABI, TBI, TCp02 before autotransplant
      and at three follow-up times after the autotransplant (4, 24 and 52 weeks); also angio-TAC of
      legs, capillaroscopy, and photoplethysmography will be evaluated at 4, and even at 52 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as measured by evaluation of any adverse event temporary correlated with the treatment</measure>
    <time_frame>52 weeks of follow-up</time_frame>
    <description>Evaluation of any adverse event temporary correlated with the treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in ischemic leg perfusion from baseline</measure>
    <time_frame>4, 22, 52 weeks of follow-up</time_frame>
    <description>Improvement of leg perfusion as assessed by values of Time to Pick (TTP) evaluated by ultrasound tools</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of Mean values of the transcutaneous partial oxygen pressure (TCP02)</measure>
    <time_frame>4, 22, 52 weeks of follow-up</time_frame>
    <description>Improvement of mean values of the transcutaneous partial oxygen pressure of at least 20%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of mean values of ankle brachial pressure index (ABI)</measure>
    <time_frame>4, 22, 52 weeks of follow-up</time_frame>
    <description>improvement (at least 25% increase) of Mean values of ankle brachial pressure index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of vessel anatomical status</measure>
    <time_frame>4, 22, 52 weeks of follow-up</time_frame>
    <description>Improvement of leg vascularization as assessed by color Doppler ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of leg perfusion</measure>
    <time_frame>4, 22, 52 weeks of follow-up</time_frame>
    <description>Improvement of leg perfusion as assessed by plethysmography characterization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of vessel anatomical status</measure>
    <time_frame>4, 22, 52 weeks of follow-up</time_frame>
    <description>Improvement of leg vascularization as assessed by Angio-CT, defined as presence of new vessels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life Improvement</measure>
    <time_frame>-28, 0, 28 weeks of follow-up</time_frame>
    <description>Quality of life, as assessed by the disease-specific ST22 and SF36 questionaries</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>improvement of rest pain</measure>
    <time_frame>4, 22, 52 weeks of follow-up</time_frame>
    <description>Rest pain as evaluated by visual analogue pain scale (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of trophic limb lesions</measure>
    <time_frame>4, 22, 52 weeks of follow-up</time_frame>
    <description>Mean score of trophic limb lesions, as evaluated according to Wagner international grade</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of numbers of major amputation (amputation free survival )</measure>
    <time_frame>4, 22, 52 weeks of follow-up</time_frame>
    <description>Reduction of numbers of major amputation compared with untreated patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>improvement of microvascular anatomy</measure>
    <time_frame>4, 22, 52 weeks of follow-up</time_frame>
    <description>evaluation of microvascular anatomy as assessed by capillaroscopy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Critical Limb Ischemia</condition>
  <arm_group>
    <arm_group_label>peripheral blood EPC injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>bone marrow MNC injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Transplantation of circulating CD14+CD34+cells</intervention_name>
    <description>intramuscular injection of circulating EPC at leg level</description>
    <arm_group_label>peripheral blood EPC injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Transplantation of BM MNC</intervention_name>
    <description>intramuscular injection of BM MNC at leg level</description>
    <arm_group_label>bone marrow MNC injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eligible patients were men and women aged more than 40 years with a diagnosis of CLI
             due to atherosclerosis of the lower extremities, as defined by the presence of
             persistent rest pain requiring systemic and continued analgesic treatment in the last
             15 days and/or the presence of trophic lesions imputable to the occluding
             arteriopathy, an ankle-brachial Index (ABI) &lt; 0.40 (with systolic ankle pressure &lt;
             50-70 Hg mm), a toe/brachial index (TBI) &lt; 0.40 (with big toe systolic pressure &lt;
             30-50 Hg mm), and a transcutaneous oxygen pressure (TC pO2) &lt; 30 Hg mm.

          -  The patient was considered as eligible for the treatment and enrolled only after the
             demonstration that intravascular or surgical re-vascularization was not possible, as
             revealed by ecography and angio-CAT, or when the patient refused to undergo surgical
             treatments and after having obtained his/her written informed consensus.

        Exclusion Criteria:

          -  Exclusion criteria were: age &lt; 40;

          -  not atherosclerotic CLI,

          -  myocardial infarction occurrence in the 6 months;

          -  cardiac failure of III-IV class NYHA;

          -  ejection fraction lower than 40%;

          -  arterial hypertension (&gt;160/100 Hg mm) uncontrolled despite the usage of two
             anti-hypertensive drugs;

          -  presence of current or chronic severe infectious diseases;

          -  osteomyelitis;

          -  diabetes with glycate hemoglobin &gt; 7.5;

          -  proliferative diabetic retinopathy;

          -  hemorrhagic disorders;

          -  non-atherosclerotic arteriopathy;

          -  chronic airway insufficiency (p02 &lt;65 Hg mm, pCO2 &gt; 0.50 Hg mm);

          -  renal failure (creatinine &gt; 2mg/dl);

          -  contraindications or intolerance to contrast media for radiologic imaging
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enrico Maggi, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florence</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Careggi</name>
      <address>
        <city>Florence</city>
        <state>Tuscany</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Weitz JI, Byrne J, Clagett GP, Farkouh ME, Porter JM, Sackett DL, Strandness DE Jr, Taylor LM. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation. 1996 Dec 1;94(11):3026-49. Review. Erratum in: Circulation 2000 Aug 29;102(9):1074.</citation>
    <PMID>8941154</PMID>
  </reference>
  <reference>
    <citation>Gregg EW, Sorlie P, Paulose-Ram R, Gu Q, Eberhardt MS, Wolz M, Burt V, Curtin L, Engelgau M, Geiss L; 1999-2000 national health and nutrition examination survey. Prevalence of lower-extremity disease in the US adult population &gt;=40 years of age with and without diabetes: 1999-2000 national health and nutrition examination survey. Diabetes Care. 2004 Jul;27(7):1591-7.</citation>
    <PMID>15220233</PMID>
  </reference>
  <reference>
    <citation>Curb JD, Masaki K, Rodriguez BL, Abbott RD, Burchfiel CM, Chen R, Petrovitch H, Sharp D, Yano K. Peripheral artery disease and cardiovascular risk factors in the elderly. The Honolulu Heart Program. Arterioscler Thromb Vasc Biol. 1996 Dec;16(12):1495-500.</citation>
    <PMID>8977454</PMID>
  </reference>
  <reference>
    <citation>Meijer WT, Grobbee DE, Hunink MG, Hofman A, Hoes AW. Determinants of peripheral arterial disease in the elderly: the Rotterdam study. Arch Intern Med. 2000 Oct 23;160(19):2934-8.</citation>
    <PMID>11041900</PMID>
  </reference>
  <reference>
    <citation>Melillo E, Nuti M, Bongiorni L, Golgini E, Balbarini A. [Major and minor amputation rates and lower critical limb ischemia: the epidemiological data of western Tuscany]. Ital Heart J Suppl. 2004 Oct;5(10):794-805. Italian.</citation>
    <PMID>15615351</PMID>
  </reference>
  <reference>
    <citation>Inglese L, Graziani L, Tarricone R. [Percutaneous treatment of peripheral obstructive arteriopathy: the reasons for a choice]. Ital Heart J Suppl. 2000 Sep;1(9):1138-47. Review. Italian.</citation>
    <PMID>11140282</PMID>
  </reference>
  <reference>
    <citation>Dzau VJ, Gnecchi M, Pachori AS, Morello F, Melo LG. Therapeutic potential of endothelial progenitor cells in cardiovascular diseases. Hypertension. 2005 Jul;46(1):7-18. Epub 2005 Jun 13. Review.</citation>
    <PMID>15956118</PMID>
  </reference>
  <reference>
    <citation>Ikenaga S, Hamano K, Nishida M, Kobayashi T, Li TS, Kobayashi S, Matsuzaki M, Zempo N, Esato K. Autologous bone marrow implantation induced angiogenesis and improved deteriorated exercise capacity in a rat ischemic hindlimb model. J Surg Res. 2001 Apr;96(2):277-83.</citation>
    <PMID>11266284</PMID>
  </reference>
  <reference>
    <citation>Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, Kearney M, Li T, Isner JM, Asahara T. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3422-7.</citation>
    <PMID>10725398</PMID>
  </reference>
  <reference>
    <citation>Iwaguro H, Yamaguchi J, Kalka C, Murasawa S, Masuda H, Hayashi S, Silver M, Li T, Isner JM, Asahara T. Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration. Circulation. 2002 Feb 12;105(6):732-8.</citation>
    <PMID>11839630</PMID>
  </reference>
  <reference>
    <citation>Iba O, Matsubara H, Nozawa Y, Fujiyama S, Amano K, Mori Y, Kojima H, Iwasaka T. Angiogenesis by implantation of peripheral blood mononuclear cells and platelets into ischemic limbs. Circulation. 2002 Oct 8;106(15):2019-25. Retraction in: Circulation. 2013 Jun 11;127(23):e842.</citation>
    <PMID>12370229</PMID>
  </reference>
  <reference>
    <citation>Tateishi-Yuyama E, Matsubara H, Murohara T, Ikeda U, Shintani S, Masaki H, Amano K, Kishimoto Y, Yoshimoto K, Akashi H, Shimada K, Iwasaka T, Imaizumi T; Therapeutic Angiogenesis using Cell Transplantation (TACT) Study Investigators. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet. 2002 Aug 10;360(9331):427-35.</citation>
    <PMID>12241713</PMID>
  </reference>
  <reference>
    <citation>Masuda H, Asahara T. Post-natal endothelial progenitor cells for neovascularization in tissue regeneration. Cardiovasc Res. 2003 May 1;58(2):390-8. Review.</citation>
    <PMID>12757873</PMID>
  </reference>
  <reference>
    <citation>Romagnani P, Annunziato F, Liotta F, Lazzeri E, Mazzinghi B, Frosali F, Cosmi L, Maggi L, Lasagni L, Scheffold A, Kruger M, Dimmeler S, Marra F, Gensini G, Maggi E, Romagnani S. CD14+CD34low cells with stem cell phenotypic and functional features are the major source of circulating endothelial progenitors. Circ Res. 2005 Aug 19;97(4):314-22. Epub 2005 Jul 14.</citation>
    <PMID>16020753</PMID>
  </reference>
  <reference>
    <citation>Chambers I, Colby D, Robertson M, Nichols J, Lee S, Tweedie S, Smith A. Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell. 2003 May 30;113(5):643-55.</citation>
    <PMID>12787505</PMID>
  </reference>
  <reference>
    <citation>Mitsui K, Tokuzawa Y, Itoh H, Segawa K, Murakami M, Takahashi K, Maruyama M, Maeda M, Yamanaka S. The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell. 2003 May 30;113(5):631-42.</citation>
    <PMID>12787504</PMID>
  </reference>
  <reference>
    <citation>Pesce M, Sch√∂ler HR. Oct-4: gatekeeper in the beginnings of mammalian development. Stem Cells. 2001;19(4):271-8. Review.</citation>
    <PMID>11463946</PMID>
  </reference>
  <reference>
    <citation>Iwama A, Oguro H, Negishi M, Kato Y, Morita Y, Tsukui H, Ema H, Kamijo T, Katoh-Fukui Y, Koseki H, van Lohuizen M, Nakauchi H. Enhanced self-renewal of hematopoietic stem cells mediated by the polycomb gene product Bmi-1. Immunity. 2004 Dec;21(6):843-51.</citation>
    <PMID>15589172</PMID>
  </reference>
  <reference>
    <citation>Melillo E, Ferrari M, Balbarini A, Pedrinelli R. Transcutaneous gases determination in diabetic critical limb ischemia. Diabetes Care. 2005 Aug;28(8):2081-2.</citation>
    <PMID>16043766</PMID>
  </reference>
  <reference>
    <citation>Becker F, Gabrielle F, Raoux MH, Brenot R, David M. [Value of measuring transcutaneous oxygen pressure in arterial disease of the legs]. Ann Cardiol Angeiol (Paris). 1989 Oct;38(8):465-72. French.</citation>
    <PMID>2596817</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2015</study_first_submitted>
  <study_first_submitted_qc>May 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2015</study_first_posted>
  <last_update_submitted>May 8, 2017</last_update_submitted>
  <last_update_submitted_qc>May 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Florence</investigator_affiliation>
    <investigator_full_name>Enrico Maggi</investigator_full_name>
    <investigator_title>Professor, MD, Director of the Unit of Immunology and Cellular Therapy</investigator_title>
  </responsible_party>
  <keyword>EPC</keyword>
  <keyword>CD34+</keyword>
  <keyword>CD14+CD34low</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

